Ovid Therapeutics (OVID) Net Cash Flow (2016 - 2026)

Ovid Therapeutics (OVID) has reported Net Cash Flow for 11 consecutive years, with -$82.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Net Cash Flow fell 1236.68% year-over-year to -$82.7 million; the trailing twelve-month figure through Jun 2026 stood at -$16.8 million (down 1213.68% YoY), and the FY2025 full-year result was -$13.0 million, down 1654.19% from the prior year.
• Net Cash Flow declined to -$82.7 million in Q2 2026 per OVID's latest filing, from $81.0 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $81.0 million in Q1 2026 and bottomed at -$93.9 million in Q2 2022.
• Historically, Net Cash Flow has averaged -$9.8 million across 5 years, with a median of -$7.5 million in 2025.
• The widest YoY moves for Net Cash Flow: up 1668.87% in 2026, down 1236.68% in 2026.
• Over 5 years, Net Cash Flow stood at -$13.4 million in 2022, then plunged by 127.01% to -$30.4 million in 2023, then jumped by 137.13% to $11.3 million in 2024, then sank by 164.61% to -$7.3 million in 2025, then slumped by 1034.81% to -$82.7 million in 2026.
• According to Business Quant data, Net Cash Flow over the past three periods registered -$82.7 million, $81.0 million, and -$7.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.